XML 27 R16.htm IDEA: XBRL DOCUMENT

Restructuring	9 Months Ended
Restructuring	Sep. 30, 2025
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In February 2024, the Company announced a strategic restructuring that reduced headcount by approximately 25% and discontinued the Company's AUR300 development program (the “February Restructuring”). In November 2024, the Company announced another strategic restructuring that further reduced headcount by approximately 45% to sharpen the Company's focus on continued LUPKYNIS growth and the development of aritinercept (the “November Restructuring”). For the nine months ended September 30, 2025, total expense for the November Restructuring was $1.6 million, which was comprised of: (i) $0.3 million for one-time termination benefits to affected employees, including severance and health care benefits; (ii) $0.1 million of contract termination costs; and (iii) $1.2 million of other restructuring costs. For the three and nine months ended September 30, 2025, the Company paid $0.1 million and $11.6 million, respectively, related to the November Restructuring costs. As of September 30, 2025 and December 31, 2024, the Company paid $16.4 million and $4.8 million, respectively, related to the November Restructuring. The Company's restructuring activities were substantially completed in the first half of 2025. For the nine months ended September 30, 2024, total expense for the February Restructuring was $7.8 million, which was comprised of: (i) $6.1 million for one-time termination benefits to affected employees, including severance and health care benefits; (ii) $1.1 million of contract termination costs; and (iii) $0.6 million of other restructuring costs. For the three and nine months ended September 30, 2024, the Company paid nil and $7.1 million, respectively, related to the February Restructuring. As of December 31, 2024, the Company had recognized all expense and made all payments related to the February Restructuring.